|Agreement labeling||Elsevier Cell Press Read & Publish|
|Has the agreement been fully disclosed and published?||Yes|
|Agreement period||01/01/2022 – 12/31/2024|
|Consortia / Institution||FinELib consortium|
Approximate range of annual corresponding author publications
|Comments on size/article output||The agreement covers Cell Press hybrid journals. The yearly allowance makes up around 100% of the output. The allowance will increase gradually during the agreement term.|
How do the costs of the agreement relate to previous subscription-only agreements with the publisher?
|Comments on cost development||Taking into account the fees previously paid to the Publisher for subscription as well as for OA publishing (APCs)|
Transfomative agreements vary by their transformative mechanisms, meaning the way in which financing is shifted from the subscription side to open access publishing. What are the characteristics of this agreement to this regard?
|Subscriptions partly converted to OA publishing fees|
Are all journals relevant to your affiliated authors (in which you expect them to publish) eligible for OA publishing under the agreement?
|Are fully open access journals covered by the agreement?||No|
|OA LICENSE||CC-BY preference, exceptions allowed|
||Original research articles
Case reports, Short communications, Short reviews (surveys), Original software publications, Data articles, Micro-articles, Replication studies, Videos, Protocols
What is the approximate share of access related costs of the overall agreement?
|More than 50%|
Are all read relevant journals covered by the agreement?
|PERPETUAL ACCESS RIGHTS||Yes|
|WORKFLOW ASSESSMENT||Too early to assess|
|Request contact to the licensee||contact [at] esac-initiative [dot] org|